Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 36

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Zhenoluten® In patients with ovarian depletion syndrome, the use of ZHENOLUTEN® and conventional therapy in 67% of cases normalized the menstrual cycle and helped reduce the astheno-neurotic manifestations of the disease. Effect of Zhenoluten®on the content of pituitary hormones in blood serum of Table 3 patients with ovarian wasting syndrome. Indicator Norm Before Treatment After Treatment with After Treatment with Conventional Drugs (Control Zhenoluten® (Primary Group) Group) FSH, (IU / ml) 1,5-45 114,6±7,8 87,2±5,4* 56,4±2,9*# LH, (IU / ml) 2-17 47,3±2,6 38,6±3,9 28,5±2,1*# Estradiol, (pmol / l) 110-734 51,1±2,6 68,3±3,1* 88,2±4,1*# * p <0.05 - significant compared with the indicator before treatment; # p <0.05 - significant compared with the indicator in patients of the control group. Laboratory data indicate a trend towards normalization of the ratio of hormones FSH, LH, and estra- diol (Table 3). Analysis of this data allows us to conclude that ZHENOLUTEN® has a normalizing effect on cellular metabolism in ovarian tissues, promotes the formation and maturation of follicles, and the restoration of the reproductive system functions in women. Thus, the results obtained indicate the therapeutic efficacy of ZHENOLUTEN® and the advisability of its use in the complex treatment of patients of different ages with menopause and ovarian deple- tion syndrome. When using ZHENOLUTEN®, no side effects, complications, or drug dependence were revealed. ZHENOLUTEN® can be used for therapeutic and prophylactic purposes in the form of a biologically active food supplement combined with any means of symptomatic and pathogenetic therapy used to treat menopausal syndrome and ovarian wasting syndrome. CONCLUSION Biologically active food supplement ZHENOLUTEN® has a normalizing effect on the functional ac- tivity of ovarian cells. ZHENOLUTEN® is well tolerated when taken orally, has no side effects, and can be used as a thera- peutic and prophylactic biologically active food supplement. ZHENOLUTEN® is recommended for use in patients with menopausal syndrome and ovarian deple- tion syndrome orally with meals, 1-2 capsules 2 times a day for 30 days. According to indications, a second course of treatment should be carried out after 3-6 months. REFERENCES 1. Bodyazhina V.I., Smetnik V.P., Tumilovich L.G. Non-Operative Gynecology: A Guide for Physicians. - M.: Medicine, 1990. -- 544 p. 2. Belousov Y.B., Moiseev V.S., Lepakhin V.K. Clinical Pharmacology and Pharmacotherapy: A Guide for Physicians. - M.: the Universe, 1993. -- 398 p. 3. Mashkovsky M.D., Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993. 4. Geriatric manual / Ed. D.F. Chebotarev, N.B. Mankovsky. – M.: Medicine, 1982. – 544 p. 5. Tepperman J., Tepperman H. Physiology of metabolism and the endocrine system: Translation from English - M.: Mir, 1989. -- 656 p.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.